Related Experiment Videos
Tiazofurin: biological effects and clinical uses
G Tricot1, H N Jayaram, G Weber
1Department of Medicine, Indiana University School of Medicine, Indianapolis.
International Journal of Cell Cloning
|May 1, 1990
Summary
Tiazofurin, a drug targeting the enzyme inosine 5'-phosphate dehydrogenase (IMPDH), shows promise in treating leukemia. By inhibiting IMPDH and guanosine triphosphate (GTP) biosynthesis, tiazofurin demonstrated clinical responses, particularly in chronic myeloid leukemia, with manageable toxicity through careful patient selection and treatment protocols.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Inosine 5'-phosphate dehydrogenase (IMPDH) is the rate-limiting enzyme in guanosine triphosphate (GTP) biosynthesis.
- Elevated IMPDH activity is characteristic of cancer cells, making it a potential chemotherapeutic target.
- Tiazofurin is a selective IMPDH inhibitor with demonstrated antiproliferative effects.
Purpose of the Study:
- To evaluate the efficacy and safety of tiazofurin in treating leukemic patients.
- To correlate biochemical markers of IMPDH inhibition with clinical outcomes.
- To establish safe administration protocols for tiazofurin in cancer therapy.
Main Methods:
- Phase I clinical trials in leukemic patients.
- Monitoring of IMPDH activity and GTP concentrations in blast cells.
- Assessment of clinical response and toxicity profiles.
Main Results:
- A strong correlation was observed between reduced IMPDH activity/GTP levels and clinical response in leukemic patients.
- The most significant responses were noted in patients with myeloid blast crisis of chronic myeloid leukemia.
- Initial severe toxicities were mitigated through improved patient selection, shorter treatment durations, and proactive management of complications.
Conclusions:
- Tiazofurin is a viable therapeutic agent for certain leukemias, particularly myeloid blast crisis.
- Biochemical monitoring of IMPDH activity and GTP levels can predict treatment response.
- Optimized treatment strategies allow for tiazofurin administration with acceptable toxicity profiles.